Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Sell
22
INBS Quote, Financials, Valuation and Earnings
Last price:
$1.47
Seasonality move
:
-33.64%
Day range:
$1.41 - $1.49
52-week range:
$1.00 - $11.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.66x
P/B ratio:
1.01x
Volume:
76.4K
Avg. volume:
121.1K
1-year change:
-64.37%
Market cap:
$6.2M
Revenue:
$3.1M
EPS (TTM):
-$35.48
Analysts' Opinion
-
Consensus RatingIntelligent Bio Solutions has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Intelligent Bio Solutions has an estimated upside of 751.06% from its current price of $1.41.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.41.
Fair Value
-
According to the consensus of 0 analysts, Intelligent Bio Solutions has 751.06% upside to fair value with a price target of -- per share.
INBS vs. S&P 500
-
Over the past 5 trading days, Intelligent Bio Solutions has overperformed the S&P 500 by 5.48% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Intelligent Bio Solutions does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Intelligent Bio Solutions has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Intelligent Bio Solutions reported revenues of $872.3K.
Earnings Growth
-
Intelligent Bio Solutions has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Intelligent Bio Solutions reported earnings per share of -$8.40.
Enterprise value:
2.5M
EV / Invested capital:
--
Price / LTM sales:
0.66x
EV / EBIT:
--
EV / Revenue:
0.80x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.24x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.5M
Return On Assets:
-86.71%
Net Income Margin (TTM):
-326.77%
Return On Equity:
-176.44%
Return On Invested Capital:
-161.24%
Operating Margin:
-312.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $2.1M | $3.2M | $796.1K | $872.3K | |
| Gross Profit | -- | $559K | $1.5M | $232.3K | $346.8K | |
| Operating Income | -$8.1M | -$9.7M | -$10.5M | -$2.5M | -$2.7M | |
| EBITDA | -$8.1M | -$10.3M | -$9.1M | -$2.1M | -$2.4M | |
| Diluted EPS | -$130.20 | -$170.83 | -$35.48 | -$12.48 | -$8.40 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.9M | $15.9M | $8.2M | $2.7M | $6.5M | |
| Total Assets | $2.9M | $19.1M | $10.2M | $8.7M | $11.7M | |
| Current Liabilities | $5.9M | $2.8M | $2.4M | $6.8M | $5.7M | |
| Total Liabilities | $6M | $5.6M | $5M | $7.5M | $5.8M | |
| Total Equity | -$3M | $13.5M | $5.2M | $1.2M | $5.9M | |
| Total Debt | -- | -- | -- | $648.1K | $499.6K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.3M | -$6.8M | -$10.6M | -$1.3M | -$2.4M | |
| Cash From Investing | -$1.4M | -- | -- | -- | -- | |
| Cash From Financing | -- | $1.4M | $14.6M | -- | $42.5K | |
| Free Cash Flow | -$5.3M | -$6.8M | -$10.6M | -$1.3M | -$2.4M | |
INBS
Sector
Market Cap
$6.2M
$48.6M
Price % of 52-Week High
12.05%
47.39%
Dividend Yield
0%
0%
Shareholder Yield
-170.16%
-0.74%
1-Year Price Total Return
-64.37%
-33.25%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.39
200-day SMA
Sell
Level
$1.97
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$1.47
Relative Strength Index (RSI14)
Buy
Level
51.18
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-52.2727
50-day SMA
Sell
Level
$1.52
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.4746)
Sell
CA Score
(Annual)
Level (-4.0975)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.5288)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).
Stock Forecast FAQ
In the current month, INBS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The INBS average analyst price target in the past 3 months is --.
-
Where Will Intelligent Bio Solutions Stock Be In 1 Year?
According to analysts, the consensus estimate is that Intelligent Bio Solutions share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Intelligent Bio Solutions?
Analysts are divided on their view about Intelligent Bio Solutions share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Intelligent Bio Solutions is a Sell and believe this share price will drop from its current level to --.
-
What Is Intelligent Bio Solutions's Price Target?
The price target for Intelligent Bio Solutions over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is INBS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Intelligent Bio Solutions is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of INBS?
You can purchase shares of Intelligent Bio Solutions via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Intelligent Bio Solutions shares.
-
What Is The Intelligent Bio Solutions Share Price Today?
Intelligent Bio Solutions was last trading at $1.47 per share. This represents the most recent stock quote for Intelligent Bio Solutions. Yesterday, Intelligent Bio Solutions closed at $1.41 per share.
-
How To Buy Intelligent Bio Solutions Stock Online?
In order to purchase Intelligent Bio Solutions stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Carlos Slim Buy PBF Energy?
Carlos Slim made a splash in a surprising sector last…
Is Booking Holdings Stock Undervalued?
There is a lot of humdrum in the market about…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 116x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Sell
47
DRUG alert for Jan 4
Bright Minds Biosciences [DRUG] is down 4.28% over the past day.
Buy
85
BMA alert for Jan 4
Banco Macro SA [BMA] is up 0.88% over the past day.
Sell
47
AGFY alert for Jan 4
Agrify [AGFY] is down 5.86% over the past day.
